Table 5. Multicopy of sufA suppresses the phenotype of the iscA erpA double mutant via IscU or via the SUF system.

Strains	Plating efficiency in the absence of mevalonate1
	−O2	+O2
ΔerpA::cat MVA+/pBAD2	≥0.5	≤10−5
ΔerpA::cat MVA+/pLAS-A2	≥0.5	≥0.5
ΔiscA ΔerpA::cat MVA+/pBAD	≤10−6	≤10−6
ΔiscA ΔerpA::cat MVA+/pLAS-A	≥0.5	≥0.5
ΔiscUA ΔerpA::cat MVA+/pBAD	≤10−6	≤10−6
ΔiscUA ΔerpA::cat MVA+/pLAS-A	≥0.5	≥0.5
ΔiscA Δsuf ΔerpA::cat MVA+/pBAD	≤10−5	≤10−6
ΔiscA Δsuf ΔerpA::cat MVA+/pLAS-A	≥0.5	≥0.5
Δsuf::cat ΔiscA MVA+/pBAD	≥0.5	≤10−5
Δsuf::cat ΔiscA MVA+/pLAS-A	≥0.5	≥0.5
Δsuf::cat ΔiscUA MVA+/pBAD	≤10−6	≤10−6
Δsuf::cat ΔiscUA MVA+/pLAS-A	≤10−6	≤10−6

¹Plating efficiency was calculated as in Table 6. Ampicillin, thiamine, nicotinic acid and arabinose were added to all plates. Plating efficiencies in anaerobiosis and presence of mevalonate were all ≥0.5.

²Similar results were obtained with the ΔsufA ΔerpA::cat MVA⁺ strain.